JCP
ACOR

Jabre Capital Partners’s Acorda Therapeutics ACOR Stock Holding History

Jabre Capital Partners’s Portfolio ACOR Stock Details ACOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-500
Closed -$1.42M – 125
2017
Q3 		$1.42M Sell
500
-333
-40% -$877K 0.28% 79
2017
Q2 		$1.97M Buy
+833
New +$1.65M 0.18% 85

Other funds holding ACOR

SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
HEC
Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jabre Capital Partners's ACOR Position: Q4 2017 in Review

Jabre Capital Partners sold out of Acorda Therapeutics (ACOR) in Q4 2017, closing a stake of 500 shares — an estimated $1.42M sold.

Jabre Capital Partners first reported a position in ACOR in Q2 2017 and held it in 2 quarters. The position peaked at $1.97M in Q2 2017. 150 funds tracked by Wall St. Rank hold ACOR as of Q4 2017.

  • Jabre Capital Partners reported no remaining Acorda Therapeutics position as of Q4 2017 after selling out during the quarter.
  • Jabre Capital Partners sold 500 Acorda Therapeutics shares in Q4 2017, an estimated $1.42M.
  • Jabre Capital Partners first reported a position in Acorda Therapeutics in Q2 2017 and held it in 2 quarters.
  • Jabre Capital Partners's Acorda Therapeutics position peaked at $1.97M in Q2 2017.
  • 150 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q4 2017.

Based on Jabre Capital Partners's 13F filing for Q4 2017, filed 14 Feb 2018.